Drug Deal Disclosure Act

This bill would require the Secretary of Health and Human Services to publish, within 30 days of enactment, records, communications, contracts, and other documents about drug pricing agreements made between the federal government and drug manufacturers on or after January 20, 2025. It covers agreements that include terms such as prices tied to those paid in other countries, direct-to-consumer sales, tariff exemptions, or special review vouchers, and it lists 17 named company agreements. Records could not be withheld for reputational or political reasons, but some proprietary or legally protected pricing information could be redacted with a written justification published in the Federal Register. The Secretary would report to Congress on what was released and withheld, and the Congressional Budget Office and Government Accountability Office would jointly report on the agreements' economic and budget effects.

Full text and official record on Congress.gov

Sponsors

• Judy Chu Democrat sponsor
• 24 cosponsors